Spotlight -

Drug Development|

Quality Systems

|Videos|May 27, 2023

Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart

Author(s)Chris Spivey

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

Image courtesy of Informa Markets

CPHI Milan Adds Sustainability Summit and New AI, Cold Chain, and Labeling Zones to 2026 Agenda

BySusan Haigney

August 11th 2026

Bristol-Myers Squibb’s new facility is a part of a $40 billion commitment the company pledged to invest in research and development, technology and domestic manufacturing | Image Courtesy of Bristol-Myers Squibb

BMS Bets on Flexible Capacity With $2.3B Texas Campus

ByZachary Zubulake

August 10th 2026

Copenhagen city skyline in Denmark at famous old Nyhavn port | Image Credit: ©f11photo -stock.adobe.com

Danish Biotechs Attracting Investor Attention

ByCheryl Barton

August 10th 2026

PharmTech Weekly Roundup—August 7, 2026

BySusan Haigney

August 7th 2026

melanoma diagnosis. the doctor examines the patient's mole | Image Credit: ©Evgeniy Kalinovskiy -stock.adobe.com

The FDA Gives Accelerated Approval to Melanoma Treatment

BySusan Haigney

August 7th 2026

Trending on Pharmaceutical Technology

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

Danish Biotechs Attracting Investor Attention

BMS Bets on Flexible Capacity With $2.3B Texas Campus

Three Formats, One Platform: Halo's New Sterile Fill-Finish Line

From Warehouse to Lakehouse: A Life Sciences Playbook for Regulated, AI-Ready Data Modernization